Eli Lilly Acquires Kelonia for $3.2B: In Vivo Genetic Meds
Eli Lilly Bolsters Genetic Medicine Pipeline With $3.2 Billion Kelonia Therapeutics Acquisition INDIANAPOLIS — In a decisive move to dominate the next frontier of oncology, Eli Lilly has announced the acquisition of Kelonia Therapeutics for $3.2 billion, signaling a massive bet on the future of internal genetic reprogramming. The deal secures a promising in vivo … Read more